291 related articles for article (PubMed ID: 22519528)
1. Proprotein convertase subtilisin kexin9 (PCSK9): a novel target for cholesterol regulation.
Basak A; Palmer-Smith H; Mishra P
Protein Pept Lett; 2012 Jun; 19(6):575-85. PubMed ID: 22519528
[TBL] [Abstract][Full Text] [Related]
2. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges.
Norata GD; Tibolla G; Catapano AL
Vascul Pharmacol; 2014 Aug; 62(2):103-11. PubMed ID: 24924410
[TBL] [Abstract][Full Text] [Related]
4. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
5. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
Christiansen MK; Jensen HK
Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
[TBL] [Abstract][Full Text] [Related]
6. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
Shen L; Peng H; Xu D; Zhao S
Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
[TBL] [Abstract][Full Text] [Related]
7. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
Avci A; Demir K; Altunkeser BB
Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
[TBL] [Abstract][Full Text] [Related]
8. The promises of PCSK9 inhibition.
Petrides F; Shearston K; Chatelais M; Guilbaud F; Meilhac O; Lambert G
Curr Opin Lipidol; 2013 Aug; 24(4):307-12. PubMed ID: 23817198
[TBL] [Abstract][Full Text] [Related]
9. Proprotein convertase subtilisin/kexin type 9: a new target molecule for gene therapy.
Banaszewska A; Piechota M; Plewa R
Cell Mol Biol Lett; 2012 Jun; 17(2):228-39. PubMed ID: 22311433
[TBL] [Abstract][Full Text] [Related]
10. Anti-PCSK9 therapies for the treatment of hypercholesterolemia.
Hooper AJ; Burnett JR
Expert Opin Biol Ther; 2013 Mar; 13(3):429-35. PubMed ID: 23240807
[TBL] [Abstract][Full Text] [Related]
11. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.
Poirier S; Mayer G
Drug Des Devel Ther; 2013; 7():1135-48. PubMed ID: 24115837
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
Lose JM; Dorsch MP; Bleske BE
Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
[TBL] [Abstract][Full Text] [Related]
13. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
Lopez D
Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
Marais AD; Kim JB; Wasserman SM; Lambert G
Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
[TBL] [Abstract][Full Text] [Related]
16. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Ling H; Burns TL; Hilleman DE
Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
[TBL] [Abstract][Full Text] [Related]
17. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
Guijarro C; Ruilope LM
Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
[No Abstract] [Full Text] [Related]
18. PCSK9 and its modulation.
Cui CJ; Li S; Li JJ
Clin Chim Acta; 2015 Feb; 440():79-86. PubMed ID: 25444750
[TBL] [Abstract][Full Text] [Related]
19. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 inhibition: current concepts and lessons from human genetics.
Rodriguez F; Knowles JW
Curr Atheroscler Rep; 2015 Mar; 17(3):487. PubMed ID: 25637042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
